Companies: 10,795·Total market cap: $144.5T

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

HKMPFOTCHealthcare● Active

$19.07

+$1.07(+5.94%)

Market Cap$4.1B

P/E Ratio—

52W High$27.96

52W Low$16.3425

Avg Volume160

Open$19.07

Beta0.65

股票排行：Drug Manufacturers - Specialty & Generic·Healthcare·查看全部市值排行 →

Hikma Pharmaceuticals PLC（HKMPF）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · HKMPF · 截至 Jun 9, 2026

关键指标

EPS (TTM)$3.45Earnings history

PE Ratio (TTM)5.5×PE Ratio deep dive

Revenue (TTM)$6.5BFull revenue history

Dividend Yield4.86%Dividend history

Shares Outstanding220.6MShares outstanding history

Next EarningsAug 6, 2026Est.Earnings history

探索 Hikma Pharmaceuticals PLC 数据

分析师预测$— · Buy

营收$3.4B+9.48%

盈利EPS $1.86+14.81%

财务快照

FY 2025Revenue$3.42B▲ +9.48% YoY

202320242025

FY 2025Net Income$410.9M▲ +14.47% YoY

202320242025

FY 2025EPS$1.86▲ +14.81% YoY

202320242025

TTM:Revenue: $6.49BNet Income: $762.0MEPS: $3.45View income statement →

分析师评级与目标价

Buy2 位分析师

Strong Buy

0

Buy

1

Hold

1

Sell

0

Strong Sell

0

12-Month Price Target

$—Low

$19.07Current

$—Avg Target

$—High

合计: 2 · 买入占比: 50.0%

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Hikma Pharmaceuticals PLC

$19.07+5.94%$4.1B #2

Sumitomo Pharma Co., Ltd.

$10.50+12.06%$4.7B #3

$52.85+4.14%$4.4B #4

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

$2.34+0.00%$6.2B #5

H. Lundbeck A/S

$7.29+0.00%$5.8B #6

H. Lundbeck A/S

$5.37-9.60%$5.7B

股票表现

1D+5.94%

1W-1.14%

1M-0.88%

3M+16.71%

YTD-8.93%

1Y-31.23%

5Y-44.32%

关于 Hikma Pharmaceuticals PLC

CEOSaid Samih Taleb Darwazah

IPO DateAug 22, 2012

Employees9,500

CountryGB

Websitehikma.com

Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications, including its own branded produ…

Drug Manufacturers - Specialty & Generic HealthcareOTCGB

关于股票概览与关键数据

Hikma Pharmaceuticals PLC（HKMPF）是 Drug Manufacturers - Specialty & Generic 行业的 Healthcare 类公司，于 Aug 22, 2012 在 OTC 上市。截至最近交易日，HKMPF 股价为 $19.07，市值约为 $4.1B。过去12个月累计回报 -31.23%，年初至今回报 -8.93%。

根据 2 位华尔街分析师，Hikma Pharmaceuticals PLC 股票共识评级为Buy，12个月平均目标价为 $—。2025 财年 Hikma Pharmaceuticals PLC 营收 $3.4B，净利润 $410.9M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，Hikma Pharmaceuticals PLC（HKMPF）股价为 $19.07，在 OTC 上市，52周区间为 $16.34 – $27.96。

HKMPF 最新股价HKMPF quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 9, 2026本内容不构成投资建议